Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

2010 • 14,016 citations

Cancer Statistics, 2010

2010 • 12,557 citations

Mutations of the BRAF gene in human cancer

2002 • 10,249 citations

Final Version of 2009 AJCC Melanoma Staging and Classification

2009 • 4,457 citations

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

2010 • 3,500 citations

Distinct Sets of Genetic Alterations in Melanoma

2005 • 2,597 citations

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

2010 • 2,120 citations

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

2010 • 1,767 citations

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

2010 • 1,729 citations

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

2010 • 1,552 citations

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

2010 • 1,438 citations

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

2010 • 1,404 citations

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

2008 • 1,305 citations

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

2000 • 1,252 citations

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

2010 • 1,218 citations

Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma

2011 • 976 citations

Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma

1999 • 756 citations

Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group

2006 • 597 citations

Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study

2004 • 469 citations

Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls

2002 • 465 citations

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

2010 • 444 citations

BRAF mutations in metastatic melanoma: a possible association with clinical outcome.

2003 • 208 citations

Oncogenic BRAF Induces Melanoma Cell Invasion by Downregulating the cGMP-Specific Phosphodiesterase PDE5A

2011 • 204 citations

BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.

2011 • 133 citations

The histologic spectrum of epithelial neoplasms induced by sorafenib

2009 • 55 citations

Sorafenib‐induced premalignant and malignant skin lesions

2011 • 35 citations

Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma.

2011 • 18 citations

Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma.

2011 • 13 citations